Watch PHAT. Know when insiders buy.
One email the day a filing lands. Free.
PHAT
Phathom Pharmaceuticals, Inc.
7.08
+0.09 +1.36%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
72
PASS · shorts 72
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $572.8MP/E —DIV YIELD —FCF YIELD -6.44%REV TTM $239.7M +110.2%NET INCOME −$99.1MNET CASH $17.9M52W 6.99 – 18.08SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $74.3M | +88.0% | 79.7% | −$4M | −$17.6M | — | -0.21 | −$1.9M | $44K | −$2M | Jul 30 |
| Q1 2026 · Mar 31 | $58.3M | +104.4% | 79.4% | −$15.5M | −$30.4M | — | -0.37 | −$15.6M | $61K | −$15.7M | Jul 30 |
| Q4 2025 · Dec 31derived | $57.6M | +94.1% | 86.7% | −$5.9M | −$21.1M | — | -0.27 | −$5M | $87K | −$5.1M | Feb 26 |
| Q3 2025 · Sep 30 | $49.5M | +202.7% | 87.5% | −$15.3M | −$30M | — | -0.41 | −$14.1M | $27K | −$14.1M | Oct 30 |
| Q2 2025 · Jun 30 | $39.5M | +439.4% | 87.2% | −$59.9M | −$75.8M | — | -1.05 | −$62.7M | $97K | −$62.8M | Jul 30 |
| Q1 2025 · Mar 31 | $28.5M | +1391.6% | 86.9% | −$78.9M | −$94.3M | — | -1.31 | −$84.9M | $18K | −$84.9M | Jul 30 |
| Q4 2024 · Dec 31derived | $29.7M | +4249.6% | 87.1% | −$59.4M | −$74.5M | — | -1.00 | −$63.5M | $5K | −$63.5M | Feb 26 |
| Q3 2024 · Sep 30 | $16.4M | — | 85.6% | −$70.8M | −$85.6M | — | -1.32 | −$63.6M | $44K | −$63.6M | Oct 30 |
| Q2 2024 · Jun 30 | $7.3M | — | 81.2% | −$77.3M | −$91.4M | — | -1.56 | −$70.7M | $46K | −$70.8M | Oct 30 |
| Q1 2024 · Mar 31 | $1.9M | — | 77.7% | −$70M | −$82.9M | — | -1.42 | −$69M | $40K | −$69.1M | Oct 30 |
| Q4 2023 · Dec 31derived | $682K | — | 75.5% | −$69.9M | −$79.6M | — | -1.45 | −$43.8M | $475K | −$44.3M | Mar 6 |
| Q3 2023 · Sep 30 | $0 | — | — | −$35.7M | −$43.2M | — | -0.76 | −$31.9M | $939K | −$32.9M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $175.1M | 87.1% | −$160M | −$221.2M | -126.3% | -3.03 | −$166.8M | $229K | −$167M | — | — |
| FY2024 · to Dec 31 | $55.3M | 85.6% | −$277.5M | −$334.3M | -605.1% | -5.29 | −$266.8M | $135K | −$266.9M | — | — |
| FY2023 · to Dec 31 | $682K | 75.5% | −$167.3M | −$201.6M | -29558.9% | -3.93 | −$137.6M | $1.6M | −$139.2M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$172.4M | −$197.7M | — | -5.05 | −$146.5M | $1M | −$147.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$135.1M | −$143.9M | — | -3.89 | −$148.5M | $328K | −$148.8M | — | — |
| FY2020 · to Dec 31 | — | — | −$125.7M | −$129.1M | — | -3.88 | −$69.7M | $1M | −$70.7M | — | — |
Every number comes from Phathom Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.